ProPhase Labs, Inc. Share Price

Equities

PRPH

US74345W1080

Healthcare Facilities & Services

Delayed Nasdaq 09:13:48 14/05/2024 pm IST 5-day change 1st Jan Change
5.05 USD -4.54% Intraday chart for ProPhase Labs, Inc. -0.20% +11.73%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 47.06M 3.93B Sales 2025 * 138M 11.54B Capitalization 95.46M 7.97B
Net income 2024 * -17M -1.42B Net income 2025 * 11M 918M EV / Sales 2024 * 2.03 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.69 x
P/E ratio 2024 *
-5.73 x
P/E ratio 2025 *
11 x
Employees 113
Yield 2024 *
-
Yield 2025 *
-
Free-Float 36.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.75%
1 week-0.94%
Current month+14.75%
1 month-18.87%
3 months+7.52%
6 months+16.65%
Current year+17.04%
More quotes
1 week
4.74
Extreme 4.735
5.55
1 month
4.45
Extreme 4.45
7.48
Current year
4.37
Extreme 4.3734
7.48
1 year
4.05
Extreme 4.05
9.94
3 years
4.05
Extreme 4.05
15.25
5 years
0.00
Extreme 0
16.04
10 years
0.00
Extreme 0
16.04
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 15/09/15
Chief Operating Officer 50 01/01
Comptroller/Controller/Auditor 49 01/22/01
Members of the board TitleAgeSince
Director/Board Member 68 01/09/01
Chief Executive Officer 64 15/09/15
Director/Board Member 44 01/15/01
More insiders
Date Price Change Volume
14/24/14 5.05 -4.54% 15 272
13/24/13 5.29 +4.75% 48,076
10/24/10 5.05 +2.64% 32,777
09/24/09 4.92 -8.72% 71,139
08/24/08 5.39 +6.52% 57,288

Delayed Quote Nasdaq, May 14, 2024 at 01:30 am IST

More quotes
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.29 USD
Average target price
18.5 USD
Spread / Average Target
+249.72%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW